Oculis, a Swiss biotech company, has raised nearly $21 million in a Series B financing round backed by investors including Novartis, Bay City Capital and Pivotal bioVenture Partners. Existing investors, including Silfurberg and Brunnur Ventures, have also participated in the round, according to Oculis' announcement. In addition, two former executives ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.